| Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer J Weisner, I Landel, C Reintjes, N Uhlenbrock, M Trajkovic-Arsic, ... Cancer research 79 (9), 2367-2378, 2019 | 85 | 2019 |
| Solid-phase synthesis of cereblon-recruiting selective histone deacetylase 6 degraders (HDAC6 PROTACs) with antileukemic activity L Sinatra, J Yang, J Schliehe-Diecks, N Dienstbier, M Vogt, P Gebing, ... Journal of Medicinal Chemistry 65 (24), 16860-16878, 2022 | 31 | 2022 |
| Development of a first-in-class small-molecule inhibitor of the C-terminal Hsp90 dimerization S Bhatia, L Spanier, D Bickel, N Dienstbier, V Woloschin, M Vogt, H Pols, ... ACS central science 8 (5), 636-655, 2022 | 24 | 2022 |
| Development of the first geldanamycin-based HSP90 degraders S Wurnig, M Vogt, J Hogenkamp, N Dienstbier, A Borkhardt, S Bhatia, ... Frontiers in Chemistry 11, 1219883, 2023 | 5 | 2023 |
| Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells M Vogt, N Dienstbier, J Schliehe-Diecks, K Scharov, JW Tu, P Gebing, ... Cell Death & Disease 14 (12), 799, 2023 | 2 | 2023 |
| Identification of non-charged 7.44 analogs interacting with the NHR2 domain of RUNX1-ETO and exhibiting an improved, selective antiproliferative effect in RUNX-ETO positive cells M Gopalswamy, D Bickel, N Dienstbier, JW Tu, S Schott-Verdugo, ... bioRxiv, 2024.06. 11.598460, 2024 | | 2024 |
| Therapeutic stratification of acute leukemia using high throughput drug screening S Bhatia, H Ahlert, N Dienstbier, J Schliehe-Diecks, M Sönnichsen, ... Klinische Pädiatrie 232 (03), 2020 | | 2020 |
| PB1648 THE CLINICAL RELEVANCE OF INDIRECT MYC INHIBITORS FOR PERSONALIZED T-ALL TREATMENT H Ahlert, S Bhatia, M Sönnichsen, N Dienstbier, M Remke, U Fischer, ... HemaSphere 3 (S1), 762-763, 2019 | | 2019 |
| Development of Small Molecule Inhibitors Targeting HSP90 C-terminal Dimerization in BCR-ABL1 positive Leukemia N Dienstbier | | |
